Menu
  • Anmelden
  • Suche

Allergologie select, Volume 5 (2021) - 1st Issue (251 - 259)

COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI)
Ludger Klimek1, Oliver Pfaar2, Eckard Hamelmann3, Jörg Kleine-Tebbe4, Christian Taube5, Martin Wagenmann6, Thomas Werfel7, Randolf Brehler8, Natalija Novak9, Norbert Mülleneisen10, Sven Becker11, Margitta Worm12
1 Center for Rhinology and Allergology, Wiesbaden, 2 Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, 3 University Hospital for Pediatrics and Adolescent Medicine, Children’s Center Bethel, University of Bielefeld, 4 Allergy Center Westend, Berlin, 5 Department of Pneumology, University Hospital Essen – Ruhrlandklinik, Essen, 6 Department of Otorhinolaryngology, University Hospital Düsseldorf, Düsseldorf, 7 Department of Dermatology, Allergology and Venerology, Hanover Medical School, 8 Department of Dermatology, University Hospital Münster, Division of Allergology, Occupational Dermatology and Environmental Medicine, Münster, 9 Department of Dermatology and Allergy, Polyclinic for Dermatology and Allergology, Bonn, 1  0 Asthma and Allergy Center, Leverkusen, 1  1 Clinic for Otorhinolaryngology, University Hospital, Tübingen, and 1  2 Allergology and Immunology, Clinic for Dermatotology, Venerology and Allergology, Charité Universitätsmedizin Berlin, Germany

   

 

DOI 10.5414/ALX02245E

Abstract

Background: Vaccinations against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are intended to induce an immune response to protect against infection/disease. Allergen immunotherapy (AIT) is thought to induce a (different) immune response, e.g., to induce tolerance to allergens. In this position paper we clarify how to use AIT in temporal relation to COVID-19 vaccination. Four SARSCoV-2 vaccines are currently approved in the EU, and their possible immunological interactions with AIT are described together with practical recommendations for use. Materials and methods: Based on the internationally published literature, this position paper provides specific recommendations for the use of AIT in temporal relation to a SARSCoV-2 vaccination. Results: AIT is used in 1) allergic rhinitis, 2) allergic bronchial asthma, 3) insect venom allergy, 4) food allergy (peanut). Conclusion: For the continuation of an ongoing AIT, we recommend an interval of 1 week before and after vaccination for subcutaneous immunotherapy (SCIT). For sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), we recommend taking Position paper them up to the day before vaccination and a break of 2 – 7 days after vaccination. Initiation of a new SCIT, SLIT, or OIT should be delayed until 1 week after the day of the second vaccination. For SCIT, we generally recommend an interval of ~ 1 week to COVID-19 vaccination.

Author Details

Authors

Departments

  • 1 Center for Rhinology and Allergology, Wiesbaden,
  • 2 Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg,
  • 3 University Hospital for Pediatrics and Adolescent Medicine, Children’s Center Bethel, University of Bielefeld,
  • 4 Allergy Center Westend, Berlin,
  • 5 Department of Pneumology, University Hospital Essen – Ruhrlandklinik, Essen,
  • 6 Department of Otorhinolaryngology, University Hospital Düsseldorf, Düsseldorf,
  • 7 Department of Dermatology, Allergology and Venerology, Hanover Medical School,
  • 8 Department of Dermatology, University Hospital Münster, Division of Allergology, Occupational Dermatology and Environmental Medicine, Münster,
  • 9 Department of Dermatology and Allergy, Polyclinic for Dermatology and Allergology, Bonn,
  • 1 
  • 0 Asthma and Allergy Center, Leverkusen,
  • 1 
  • 1 Clinic for Otorhinolaryngology, University Hospital, Tübingen, and
  • 1 
  • 2 Allergology and Immunology, Clinic for Dermatotology, Venerology and Allergology, Charité Universitätsmedizin Berlin, Germany

Address

Prof. Dr. med. Ludger Klimek, Zentrum für Rhinologie und Allergologie, An den Quellen 10, 65183 Wiesbaden, Germany
Email: [email protected]

Citation

Ludger Klimek, Oliver Pfaar, Eckard Hamelmann, Jörg Kleine-Tebbe, Christian Taube, Martin Wagenmann, Thomas Werfel, Randolf Brehler, Natalija Novak, Norbert Mülleneisen, Sven Becker, and Margitta Worm.COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). 2021; 5: 251-259. doi: 10.5414/ALX02245E.

###article_not_exists_msg###

Warenkorb Übersicht

Warenkorb Übersicht
Typ Anz Rabatt MwSt Preis
Der Warenkorb ist leer
Ihr Warenkorb